No Data
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
JPMorgan Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $15 From $10
Solid Biosciences (SLDB) has an average outperform rating and a price target range of $6 to $42, according to analysts polled by Capital IQ.Price: 8.65, Change: +0.74, Percent Change: +9.36
J.P. Morgan Upgrades Solid Biosciences(SLDB.US) to Buy Rating, Raises Target Price to $15
J.P. Morgan analyst Anupam Rama upgrades $Solid Biosciences(SLDB.US)$ to a buy rating, and adjusts the target price from $10 to $15.According to TipRanks data, the analyst has a success rate of 48.8%
Express News | Solid Biosciences Inc : JP Morgan Raises Target Price to $15 From $10
Express News | Solid Biosciences Inc : JP Morgan Raises to Overweight From Neutral